C-23

A Retrospective Review of Patients' Octreotide Administration During 177Lu-Dotatate Treatment

Kimberly Freitas[1], Erik Mittra[1]

[1]Oregon Health & Science University, Portland, Oregon, USA

BACKGROUND

Both the NETTER-1 and NETTER-2 trials demonstrated improved progression-free survival (PFS) for GEP-NET patients receiving ^{177}Lu-Dotatate with Octreotide LAR over Octreotide LAR monotherapy. In both studies, the Octreotide LAR or synthetic somatostatin analog (SSA) was administered 28 days before ^{177}Lu-Dotatate. Since then, many institutions and the Lutathera package insert continue to emphasize a 28-day SSA washout. This regimen relies heavily on adept interdepartmental coordination and high patient health literacy, and it remains unclear how meaningful and practical this washout is in everyday practice.

METHODS

Charts were evaluated from 20 GEP-NET patients who received ^{177}Lu-Dotatate at Oregon Health and Science University (OHSU) between 11/22/2023-6/10/2025. All patients had progressed on SSAs. At OHSU, SSAs are only administered during ^{177}Lu-Dotatate for patients with functional tumors. Documentation was reviewed to determine whether SSAs were continued during ^{177}Lu-Dotatate treatments, if there was 28-day washout, and whether patients had progressed at time of review.

RESULTS

Of the 20 patients evaluated, 11 patients stopped Octreotide LAR 28 days prior to their first dose of ^{177}Lu-Dotatate and 9 patients continued with SSAs. While only 1 patient on SSAs had clear documentation regarding the timing of injections, 6 of the SSA patients continued to have 28-day washouts between treatments. The 3 other SSA patients received injections within 28 days of treatment (17- 25 days, mean 20.7).

At time of review, 14 of 20 patients (70%) had ongoing PFS which ranged from 386-699 days since last ^{177}Lu-Dotatate administration. For the other 6 patients, time to documented progressive disease (PD) ranged from 209-666 days.

Table: SSA Usage During ^{177}Lu-Dotatate Treatment and Relationship to PFS and PD

	SSA Stopped N= 11	SSAs with 28 Day Washout N= 6	SSAs with Less than 28 Day Washout N= 3
PFS n	7	5	2
Range of Days Since ^{177}Lu-Dotatate	392-650	386-699	390-399
Mean Days	508	525.5	394.5
PD n	4	1	1
Range of Days Since ^{177}Lu-Dotatate	209-456	666	348
Mean Days	337.3	666	348

CONCLUSIONS

This is preliminary data. Further patients and time points are needed to better understand the optimal timing of Octreotide LAR administration during ^{177}Lu-Dotatate treatments. This retrospective review discovered that many patients continued to abide by the 28-day washout, yet 2 patients received injections closer to their treatments and continued to have PFS at the time of review.

ABSTRACT ID #36609